Updated Jul 16, 2026
Forbion Growth Opportunities Fund I Cooperatief U.A. is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market purchases: $8.01M. Historical track record: 4/5 stars across 14 tracked purchases.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★★★★☆ (4/5) |
|---|---|
| Total purchases tracked | 14 |
| Purchases with forward-return data | 14 |
| 30-day win rate | 7143% |
| 90-day win rate | 9286% |
| Avg 5-day return | +674.59% |
| Avg 30-day return | +2039.25% |
| Avg 90-day return | +3209.68% |
| Best 30-day return | +4611.57% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-11-01 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 561.8K | $8.90 | $5.00M |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 800 | $6.60 | $5K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 11.8K | $6.55 | $78K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 6.0K | $6.54 | $39K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 5.8K | $6.48 | $37K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 10.2K | $6.37 | $65K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 35.3K | $6.44 | $227K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 341.3K | $6.34 | $2.16M |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 3.2K | $6.38 | $21K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 38.4K | $5.94 | $228K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 9.6K | $9.09 | $87K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 400 | $8.30 | $3K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 5.0K | $7.69 | $39K |
| 2024-10-18 | ENGN | enGene Therapeutics Inc. | P — Open-market purchase | 2.8K | $7.17 | $20K |
Forbion Growth Opportunities Fund I Cooperatief U.A. is a corporate insider — currently tracked as Insider. InsiderAlpha tracks every SEC Form 4 filing in real time.
Recorded transactions: 14 open-market purchases ($8.01M) and 0 open-market sales () across all tracked filings.
Across 14 tracked purchases, Forbion Growth Opportunities Fund I Cooperatief U.A. averaged +2039.2% avg 30-day return with a 7143% 30-day win rate. InsiderAlpha rates the track record at 4/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Forbion Growth Opportunities Fund I Cooperatief U.A. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.